BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Risperidone (Risperdal) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Risperidone (Risperdal)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04478838-9193@assetmemo.bio
DTSTAMP:20261121T004427Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Risperidone (Risperdal): Phase 4 readout est. (NCT04478838)
DESCRIPTION:Risperidone (Risperdal)\, phase 4\, Schizophrenia.\nStudy: "Ext
 ended" (Alternate Day) Antipsychotic Dosing\nEstimated primary completion:
  30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 isperidone-risperdal#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04478838
URL:https://assetmemo.bio/drug/risperidone-risperdal#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665073-9193@assetmemo.bio
DTSTAMP:20261121T004427Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Risperidone (Risperdal): Phase 4 readout est. (NCT07665073)
DESCRIPTION:Risperidone (Risperdal)\, phase 4\, Bipolar Disorder.\nStudy: R
 isperidone vs Cariprazine in Acute Mania\nEstimated primary completion: Ju
 ne 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/risperidone-
 risperdal#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07665073
URL:https://assetmemo.bio/drug/risperidone-risperdal#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483294-9193@assetmemo.bio
DTSTAMP:20261121T004427Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Risperidone (Risperdal): Phase 4 readout est. (NCT07483294)
DESCRIPTION:Risperidone (Risperdal)\, phase 4.\nStudy: Cerebellum-based Ima
 ging Neural Markers for Antipsychotic Response\nEstimated primary completi
 on: 1 December 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 risperidone-risperdal#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07483294
URL:https://assetmemo.bio/drug/risperidone-risperdal#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969755-9193@assetmemo.bio
DTSTAMP:20261121T004427Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Risperidone (Risperdal): Phase 4 readout est. (NCT06969755)
DESCRIPTION:Risperidone (Risperdal)\, phase 4\, Schizophrenia.\nStudy: Biom
 arkers to Enhance Early Schizophrenia Treatment\nEstimated primary complet
 ion: 30 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 speridone-risperdal#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06969755
URL:https://assetmemo.bio/drug/risperidone-risperdal#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152184-9193@assetmemo.bio
DTSTAMP:20261121T004427Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Risperidone (Risperdal): Phase 2 readout est. (NCT07152184)
DESCRIPTION:Risperidone (Risperdal)\, phase 2\, Schizophrenia.\nStudy: Stud
 y Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Pati
 ents With Schizophrenia Spectrum Disorder: a Personalized Medicine Approac
 h\nEstimated primary completion: 1 February 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/risperidone-risperdal#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07152184
URL:https://assetmemo.bio/drug/risperidone-risperdal#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
